An algorithm for the pre-operative differentiation of benign ovarian tumours based on magnetic resonance imaging interpretation in a regional core hospital: A retrospective study
CONCLUSIONS: Among four types of OTs (OEC, OMCT, OEA and OCCA), MRI interpretation was able to differentiate between Be-OTs and Bo/Ma-OTs almost perfectly. Additionally, to mitigate the difficulty in differentiating SM-OTs, OT size may be useful in combination with MRI findings, although further accumulation and analysis of OT cases is needed.PMID:38058586 | PMC:PMC10696378 | DOI:10.1016/j.eurox.2023.100260 (Source: Reproductive Biology)
Source: Reproductive Biology - December 7, 2023 Category: Reproduction Medicine Authors: Wataru Isono Hiroko Tsuchiya Reiko Matsuyama Akihisa Fujimoto Osamu Nishii Source Type: research
An algorithm for the pre-operative differentiation of benign ovarian tumours based on magnetic resonance imaging interpretation in a regional core hospital: A retrospective study
CONCLUSIONS: Among four types of OTs (OEC, OMCT, OEA and OCCA), MRI interpretation was able to differentiate between Be-OTs and Bo/Ma-OTs almost perfectly. Additionally, to mitigate the difficulty in differentiating SM-OTs, OT size may be useful in combination with MRI findings, although further accumulation and analysis of OT cases is needed.PMID:38058586 | PMC:PMC10696378 | DOI:10.1016/j.eurox.2023.100260 (Source: Reproductive Biology)
Source: Reproductive Biology - December 7, 2023 Category: Reproduction Medicine Authors: Wataru Isono Hiroko Tsuchiya Reiko Matsuyama Akihisa Fujimoto Osamu Nishii Source Type: research
An algorithm for the pre-operative differentiation of benign ovarian tumours based on magnetic resonance imaging interpretation in a regional core hospital: A retrospective study
CONCLUSIONS: Among four types of OTs (OEC, OMCT, OEA and OCCA), MRI interpretation was able to differentiate between Be-OTs and Bo/Ma-OTs almost perfectly. Additionally, to mitigate the difficulty in differentiating SM-OTs, OT size may be useful in combination with MRI findings, although further accumulation and analysis of OT cases is needed.PMID:38058586 | PMC:PMC10696378 | DOI:10.1016/j.eurox.2023.100260 (Source: Reproductive Biology)
Source: Reproductive Biology - December 7, 2023 Category: Reproduction Medicine Authors: Wataru Isono Hiroko Tsuchiya Reiko Matsuyama Akihisa Fujimoto Osamu Nishii Source Type: research
Serial circulating-tumor DNA analysis with a tumor na ïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer
Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429. Online ahead of print.ABSTRACTCirculating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. Here, we aimed to assess the clinical utility of serial ctDNA testing using tumor-naïve, small-sized next-generation sequencing (NGS) panels. A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples. Patients received adjuvant therapy based on the cu...
Source: Cell Research - December 1, 2023 Category: Cytology Authors: Jinho Heo Yoo-Na Kim Saeam Shin Kyunglim Lee Ji-Hyun Lee Yong Jae Lee Zisun Choi Jihyang Park Seungki Min Sang Wun Kim Jong Rak Choi Sunghoon Kim Seung-Tae Lee Jung-Yun Lee Source Type: research
Serial circulating-tumor DNA analysis with a tumor na ïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer
Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429. Online ahead of print.ABSTRACTCirculating tumor DNA (ctDNA) may aid in personalizing ovarian cancer therapeutic options. Here, we aimed to assess the clinical utility of serial ctDNA testing using tumor-naïve, small-sized next-generation sequencing (NGS) panels. A total of 296 patients, including 201 with ovarian cancer and 95 with benign or borderline disease, were enrolled. Samples were collected at baseline (initial diagnosis or surgery) and every 3 months after that, resulting in a total of 811 blood samples. Patients received adjuvant therapy based on the cu...
Source: Cell Research - December 1, 2023 Category: Cytology Authors: Jinho Heo Yoo-Na Kim Saeam Shin Kyunglim Lee Ji-Hyun Lee Yong Jae Lee Zisun Choi Jihyang Park Seungki Min Sang Wun Kim Jong Rak Choi Sunghoon Kim Seung-Tae Lee Jung-Yun Lee Source Type: research
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
This study is registered with ClinicalTrials.gov, NCT03340974, and is complete.FINDINGS: Between Jan 25, 2018, and April 29, 2020, 47 patients were screened, of whom 42 were enrolled (median age was 71 years [IQR 63-75], 23 [55%] were male, 19 [45%] were female, 37 [88%] were White, three [7%] were Black, and one [2%] each were unknown or other races) and randomly assigned to avasopasem (n=24) or placebo (n=18); the placebo group was terminated early after failing to meet prespecified efficacy parameters. At data cutoff (June 28, 2021), the avasopasem group satisfied boundaries for both efficacy and toxicity. Late onset Ef...
Source: Pain Physician - December 1, 2023 Category: Anesthesiology Authors: Cullen M Taniguchi Jessica M Frakes Todd A Aguilera Manisha Palta Brian Czito Manoop S Bhutani Lauren E Colbert Joseph Abi Jaoude Vincent Bernard Shubham Pant Ching-Wei D Tzeng Dae Won Kim Mokenge Malafa James Costello Geena Mathew Neal Rebueno Eugene J K Source Type: research
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
This study is registered with ClinicalTrials.gov, NCT03340974, and is complete.FINDINGS: Between Jan 25, 2018, and April 29, 2020, 47 patients were screened, of whom 42 were enrolled (median age was 71 years [IQR 63-75], 23 [55%] were male, 19 [45%] were female, 37 [88%] were White, three [7%] were Black, and one [2%] each were unknown or other races) and randomly assigned to avasopasem (n=24) or placebo (n=18); the placebo group was terminated early after failing to meet prespecified efficacy parameters. At data cutoff (June 28, 2021), the avasopasem group satisfied boundaries for both efficacy and toxicity. Late onset Ef...
Source: Pain Physician - December 1, 2023 Category: Anesthesiology Authors: Cullen M Taniguchi Jessica M Frakes Todd A Aguilera Manisha Palta Brian Czito Manoop S Bhutani Lauren E Colbert Joseph Abi Jaoude Vincent Bernard Shubham Pant Ching-Wei D Tzeng Dae Won Kim Mokenge Malafa James Costello Geena Mathew Neal Rebueno Eugene J K Source Type: research
Metabolic coupling in phyllodes tumor of the breast and its association with tumor progression
Oncol Lett. 2023 Nov 3;26(6):545. doi: 10.3892/ol.2023.14132. eCollection 2023 Dec.ABSTRACTThere are markers of metabolic coupling in breast cancer. Loss of caveolin-1 (Cav-1) and upregulation of monocarboxylate transporters (MCTs), especially MCT1 and MCT4, serve an important role in metabolic coupling necessary for release and uptake of metabolites. However, the occurrence of these phenomena in phyllodes tumors (PTs) of the breast is unclear. A total of 101 PTs (60 benign, 26 borderline and 15 malignant) and nine breast tissue samples with no pathological lesions were analyzed. Immunohistochemical staining for Cav-1, MCT...
Source: Oncology Letters - November 29, 2023 Category: Cancer & Oncology Authors: Nah Ihm Kim Min Ho Park Sun-Seog Kweon Ji Shin Lee Source Type: research
